Calendario›REGN›REGN7508 · ROXI-PALISADE
REGN7508 · ROXI-PALISADE
Reducing Adverse Vascular Outcomes With Factor XI Inhibition in Adult Participants With Peripheral Artery Disease
Ensayo de REGENERON PHARMACEUTICALS, INC. en Enfermedad arterial periferica (PAD).
- Fase
- Fase 3
- Estado
- Reclutando pacientes
- Participantes
- 7.050
- Centros
- 20
- Fin del objetivo primario
- ago 2029
Qué significa cada fase y cada estado.
Estudio de intervención, aleatorizado, cuádruple ciego. Comenzó en jul 2026.
Qué mide
Tiempo hasta la primera aparicion de un evento vascular tromboticomayor, consistente en isquemia aguda de extremidades (ALI), amputacion mayor (por encima del tobillo) de etiologia vascular, infarto de miocardio (IM), ictus isquemico o muerte cardiovascular (CV) (Approximately up to 42 months) (del registro, en inglés)
Qué se prueba
Se estudian los farmacos experimentales REGN7508 y REGN9933, comparados individualmente con rivaroxaban y placebo, para prevenir coagulos sanguineos potencialmente mortales en personas con enfermedad arterial periferica que han tenido revascularizacion de la extremidad inferior.
Lo que dice el documentohow well REGN7508 and REGN9933 prevent life-threatening blood clots in participants with PAD who have recently had LER. The effects of REGN7508 and REGN9933, individually, will also be compared to rivaroxaban and a placebo.
Traducción automática (claude-sonnet-5). Lo comprobado es la cita: está literal en el documento y sus cifras cuadran con las de la frase. Todavía no la ha leído una persona.
Cómo lo describe el promotor
En el documentoEn inglés, del registroThis study is researching 2 different experimental drugs called REGN7508 and REGN9933. The study is focused on people who have Peripheral Artery Disease (PAD), which means that the blood vessels in their arms and legs have become too narrow. People with PAD have a higher risk of getting blood clots after procedures like Lower Extremity Revascularization (LER), a procedure to improve blood flow in the legs and feet. The aim of this study is to see how well REGN7508 and REGN9933 prevent life-threatening blood clots in participants with PAD who have recently had LER. The effects of REGN7508 and REGN9933, individually, will also be compared to rivaroxaban and a placebo. The study is looking at several other research questions, including: * What side effects might happen from taking the study drugs and how do they compare to the side effects of rivaroxaban * How much study drug is in the blood at different times * Whether the body makes antibodies against the study drugs (which could make the drugs less effective or could lead to side effects) * If the study drugs affect the ability of the blood to clot normally
Más ensayos de REGN
| Ensayo | Fase | Estado | Lectura de resultados |
|---|---|---|---|
| cemiplimab | Fase 2 | En marcha, sin reclutar | mar 2025 (real) |
| Pozelimab + Cemdisiran · NIMBLE | Fase 3 | En marcha, sin reclutar | jul 2025 (real) |
| Garetosmab · OPTIMA | Fase 3 | En marcha, sin reclutar | jul 2025 (real) |
| Aflibercept 8 mg · ELARA | Fase 3 | En marcha, sin reclutar | ago 2025 (real) |
| Dupilumab · ENGAGE | Fase 2 | En marcha, sin reclutar | feb 2026 (real) |
| Fianlimab | Fase 3 | En marcha, sin reclutar | mar 2026 (real) |
Todos los de REGN, en su ficha.
Ficha completa en ClinicalTrials.gov (NCT07318610), actualizada en sep 2026.